title: [Antihypertensive and antiischemic effectiveness and safety of the AT1-receptor blocker irbesartranin arterial hypertension in patients with prior myocardial infarction].
abstract: Thirty males with prior myocardial infarction concurrent with arterial hypertension (AH) were examined to study the antihypertensive and antiischemic effects of the AT1-receptor blocker irbesartran. Group 1 comprised 12 (40%) patients with mild AH; Group 2 included 18 (60%) with moderate AH. In Group 2, the standard therapy with irbesartan in a single dose of 150 mg in the morning was supplemented by the beta1-adrenoblocker atenolol in the average daily dose of 31.25 mg. In Group 1 patients there were decreases in systolic blood pressure (SBP) by 28% and diastolic blood pressure (DBA) by 19% while in Group 2 receiving combined therapy with atenolol, SBP lowered on the average of 38.3 mm Hg of the baseline values and DBA became normal in 66.7% of the patients (p < 0.00). Thus, irbesartan provides good antihypertensive and antiischemic effects in patients with grade 1 AH; the combined therapy enhances the efficiency of treatment by 92% in patients with moderate AH.
authors.forename: A T
authors.initials: AT
authors.lastname: Tepliakov
authors.forename: T A
authors.initials: TA
authors.lastname: Stepacheva
authors.forename: O A
authors.initials: OA
authors.lastname: Ivannikova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Pushnikova
authors.forename: V V
authors.initials: VV
authors.lastname: Kaliuzhin
authors.forename: E V
authors.initials: EV
authors.lastname: Malakhovich
authors.forename: E V
authors.initials: EV
authors.lastname: Makushkin
authors.forename: M V
authors.initials: MV
authors.lastname: Zenevich
mesh_terms: D000284:Administration, Oral; D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001262:Atenolol / Q000008:administration & dosage; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects*; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D004359:Drug Therapy, Combination; D004452:Echocardiography; D005500:Follow-Up Studies; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000077405:Irbesartan; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D015635:Radionuclide Ventriculography; D013777:Tetrazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D001262:Atenolol; D000077405:Irbesartan